2. Academic Validation
  3. TLR Agonists Delivered by Plant Virus and Bacteriophage Nanoparticles for Cancer Immunotherapy

TLR Agonists Delivered by Plant Virus and Bacteriophage Nanoparticles for Cancer Immunotherapy

  • Bioconjug Chem. 2023 Aug 23. doi: 10.1021/acs.bioconjchem.3c00271.
Eunkyeong Jung 1,  Young Hun Chung 2 3,  Nicole F Steinmetz 1 2 3 4 5 6
Affiliations

Affiliations

  • 1 Department of NanoEngineering, University of California, San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States.
  • 2 Department of Bioengineering, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States.
  • 3 Moores Cancer Center, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States.
  • 4 Center for Nano-ImmunoEngineering, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States.
  • 5 Department of Radiology, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States.
  • 6 Institute for Materials Discovery and Design, University of California San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States.
PMID: 37611278 DOI: 10.1021/acs.bioconjchem.3c00271
Abstract

Toll-like receptors (TLRs) are promising targets in Cancer Immunotherapy due to their role in activating the immune system; therefore, various small-molecule TLR agonists have been tested in clinical applications. However, the clinical use of TLR agonists is hindered by their non-specific side effects and poor pharmacokinetics. To overcome these limitations, we used plant virus nanoparticles (VNPs) and bacteriophage virus-like particles (VLPs) as drug delivery systems. We conjugated TLR3 or TLR7 agonists to cowpea mosaic virus (CPMV) VNPs, cowpea chlorotic mottle virus (CCMV) VNPs, and bacteriophage Qβ VLPs. The conjugation of TLR7 Agonist, 2-methoxyethoxy-8-oxo-9-(4-carboxybenzyl)adenine (1V209), resulted in the potent activation of immune cells and promoted the production of pro-inflammatory cytokine interleukin 6. We found that 1V209 conjugated to CPMV, CCMV, and Qβ reduced tumor growth in vivo and prolonged the survival of mice compared to those treated with free 1V209 or a simple admixture of 1V209 and viral particles. Nucleic acid-based TLR3 Agonist, polyinosinic acid with polycytidylic acid (poly(I:C)), was also delivered by CPMV VNPs, resulting in enhanced mice survival. All our data suggest that coupling and co-delivery are required to enhance the anti-tumor efficacy of TLR agonists and simple mixing of the VLPs with the agonists does not confer a survival benefit. The delivery of 1V209 or poly(I:C) conjugated to VNPs/VLPs probably enhances their efficacy due to the multivalent presentation, prolongation of tumor residence time, and targeting of the innate immune cells mediated by the VNP/VLP carrier.

Figures
Products